Shares of InfuSystem Holdings, Inc. (NYSEAMERICAN:INFU – Get Free Report) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $7.97. InfuSystem shares last traded at $7.78, with a volume of 18,679 shares changing hands.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of InfuSystem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 17th.
Check Out Our Latest Stock Analysis on INFU
InfuSystem Price Performance
Hedge Funds Weigh In On InfuSystem
Several hedge funds have recently bought and sold shares of INFU. Heartland Advisors Inc. lifted its position in shares of InfuSystem by 17.6% in the 3rd quarter. Heartland Advisors Inc. now owns 500,000 shares of the medical instruments supplier’s stock worth $4,820,000 after purchasing an additional 75,000 shares during the period. Citigroup Inc. boosted its stake in InfuSystem by 124.1% in the 3rd quarter. Citigroup Inc. now owns 50,640 shares of the medical instruments supplier’s stock worth $488,000 after purchasing an additional 28,038 shares in the last quarter. First Eagle Investment Management LLC grew its position in InfuSystem by 29.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 468,400 shares of the medical instruments supplier’s stock worth $4,515,000 after purchasing an additional 107,001 shares during the last quarter. Barclays PLC purchased a new position in shares of InfuSystem in the second quarter worth $35,000. Finally, Punch & Associates Investment Management Inc. lifted its stake in shares of InfuSystem by 3.2% during the third quarter. Punch & Associates Investment Management Inc. now owns 939,918 shares of the medical instruments supplier’s stock worth $9,061,000 after buying an additional 28,807 shares during the period. Institutional investors own 71.13% of the company’s stock.
About InfuSystem
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Featured Articles
- Five stocks we like better than InfuSystem
- How Can Investors Benefit From After-Hours Trading
- High-Yield Texas Instruments Could Hit New Highs Soon
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for InfuSystem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InfuSystem and related companies with MarketBeat.com's FREE daily email newsletter.